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Motility measurementa b s t r a c t
A major hindrance to evaluating nematode populations for anthelmintic resistance, as well as for screen-
ing existing drugs, new compounds, or bioactive plant extracts for anthelmintic properties, is the lack of
an efﬁcient, objective, and reproducible in vitro assay that is adaptable to multiple life stages and parasite
genera. To address this need we have developed the ‘‘Worminator’’ system, which objectively and quan-
titatively measures the motility of microscopic stages of parasitic nematodes. The system is built around
the computer application ‘‘WormAssay’’, developed at the Center for Discovery and Innovation in Para-
sitic Diseases at the University of California, San Francisco. WormAssay was designed to assess motility
of macroscopic parasites for the purpose of high throughput screening of potential anthelmintic com-
pounds, utilizing high deﬁnition video as an input to assess motion of adult stage (macroscopic) parasites
(e.g. Brugia malayi). We adapted this assay for use with microscopic parasites by modifying the software
to support a full frame analysis mode that applies the motion algorithm to the entire video frame. Thus,
the motility of all parasites in a given well are recorded and measured simultaneously. Assays performed
on third-stage larvae (L3) of the bovine intestinal nematode Cooperia spp., as well as microﬁlariae (mf) of
the ﬁlarioid nematodes B. malayi and Diroﬁlaria immitis, yielded reproducible dose responses using the
macrocyclic lactones ivermectin, doramectin, and moxidectin, as well as the nicotinic agonists, pyrantel,
oxantel, morantel, and tribendimidine. This new computer based-assay is simple to use, requires minimal
new investment in equipment, is robust across nematode genera and developmental stage, and does not
require subjective scoring of motility by an observer. Thus, the ‘‘Worminator’’ provides a relatively low-
cost platform for developing genera- and stage-speciﬁc assays with high efﬁciency and reproducibility,
low labor input, and yields objective motility data that is not subject to scorer bias.
 2014 The Authors. Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Anthelmintic resistance of gastrointestinal nematode (GIN)
parasites constitutes a major problem for livestock health and
productivity around the world (Fleming et al., 2006; Kaplan and
Vidyashankar, 2012). The common practice of intensive farming
methods coupled with heavy reliance on anthelmintics has
resulted in a serious escalation in the prevalence, distribution,and scope of AR in many of the most important GIN parasite spe-
cies. In sheep and goats the situation is the most severe, with
increasing number of farms around the world experiencing resis-
tance to all classes of available anthelmintics (Howell et al.,
2008; Almeida et al., 2010; Sczesny-Moraes et al., 2010). Multiple
anthelmintic resistance in GIN parasites of cattle (Sutherland and
Leathwick, 2011) and horses (von Samson-Himmelstjerna, 2012;
Canever et al., 2013) is also being increasingly reported raising
the level of concern in these hosts. In contrast to the situation with
GIN, until recently the ﬁlarioid parasites, such as Diroﬁlaria immitis,
were considered to be at a low risk for developing AR (Prichard,
2005). However, reports of resistance to several currently available
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et al., 2011) have proven these predictions wrong. Though AR is
not yet a problem in human nematodes, sub-optimal responses
of ivermectin against Onchocerca volvulus (Osei-Atweneboana
et al., 2007; Churcher et al., 2009), and the potential for heavy drug
selection pressures on populations of soil transmitted helminths
(STH) due to scale up of Mass Drug Administration (MDA) pro-
grams are raising serious concerns (Churcher et al., 2010; Keenan
et al., 2013).
In vitro assays are the most efﬁcient and cost effective means of
diagnosing and characterizing anthelmintic resistance in nema-
tode populations. Additionally, in vitro assays are an essential com-
ponent of new anthelmintic compound testing/discovery. Highly
sophisticated instrumentation has been developed to quantita-
tively measure motility of microscopic stages of parasites (e.g.
Lemnatec Scanalyzer™ HTS, Aachen Germany) with high through-
put, but these instruments are extremely expensive to purchase,
costing several hundred thousand dollars. Additionally they are
extremely expensive to maintain, making them impractical and
unavailable to most all but the well-ﬁnanced laboratories of the
pharmaceutical industry.
Currently, there are several low-throughput in vitro assays avail-
able for screening new compounds for anthelmintic activity and for
diagnosing anthelmintic resistance in nematode populations; these
are the egg hatch assay (EHA) (LeJambre, 1976), the larval develop-
ment assay (LDA) (Taylor, 1990; Coles et al., 2006), the larval migra-
tion inhibition assay (LMIA) (Wagland et al., 1992), and the larval
motility assay (LMA) (Martin and Le Jambre, 1979). All of these
assays were originally developed for diagnosing anthelmintic resis-
tance in strongylid nematode parasites of sheep, and a few have
beenmodiﬁed for use in related nematode species of other livestock
hosts. The LMA has been adapted for sensitivity testing of anthel-
mintics for hookworm and Strongyloides spp. (Kotze et al., 2004,
2005), both being human STH. Validation of this assay for the detec-
tion of resistance has not been possible due to the lack of conﬁrmed
resistant isolates (this is also true for all in vitro assays relating to
human STH at the time of this writing).
The LMIA and LMA utilize motility as an indicator of larval
health and drug effectiveness and thus have the least limitations
with regard to stage and species. However, to date these assays
have not been well standardized across laboratories, and despite
numerous publications that describe the LMIA, no consistent pro-
tocol has been established (Matthews et al., 2012). However, in
one study, inter-lab variability was shown to be low when stan-
dardized protocols for LMIA were used on the same parasite iso-
lates (Demeler et al., 2010a). The LMIA is based on the ability of
larvae to migrate through a ﬁne mesh screen, with larvae that
are negatively affected by the test compound less able to migrate
through the mesh. A major limiting factor to this assay is differing
sizes of larval stages of different parasite species requiring custom
selection of mesh size for every species; (Kotze et al., 2006;
Demeler et al., 2010a; Evans et al., 2013). While this issue is not
important in research laboratories where mono-speciﬁc samples
are available and assays can be customized for the species being
tested, it prevents this assay from being useful in diagnostic sam-
ples containing multiple species. Additionally, only one time point
for migration can be tested in a single assay, thus numerous assays
must be done to optimize incubation and migration periods for
each nematode species and drug. The LMA requires an observer
to assign a motility score for each larva on a 0–3 scale, or to classify
it as motile (thrashing) or non-motile (moving in a restricted
manner or still) (Gill et al., 1991). Consequently, the LMA is highly
subjective, vulnerable to reader bias, poorly quantitative, and
extremely low throughput.
The ﬁrst use of technology to improve the measurement and
analysis of nematode motility was the micromotility meter(Bennett and Pax, 1986). This instrument uses photo-detectors to
measure changes in light refraction due to motility of parasites.
The micromotility meter technology is covered under US Patent
#4,603,977 (Bennett et al., 1986) and was sold through B & P
Instruments (Mason, MI, USA). The inventors demonstrated the
utility of this instrument by measuring the motility of a number
of different helminths (including both nematodes and trematodes)
and stages (Bennett and Pax, 1987). Subsequently, several labs
have attempted to develop in vitro assays to detect anthelmintic
resistance using the micromotility meter, with mixed results
(Folz et al., 1987; Coles et al., 1989; Várady et al., 1998; Demeler
et al., 2010b). Thus, despite offering an improvement in technol-
ogy, this instrument has not gained wide usage, and has not led
to new validated assays of importance.
Recent technological developments have facilitated the adapta-
tion of computer image processing coupled with high deﬁnition
video for studying and characterizing the motion of nematodes
(Krajacic et al., 2012). WormAssay is a speciﬁc application of this
type of technology developed at the University of California, San
Francisco (UCSF). The WormAssay application utilizes high deﬁni-
tion (HD) video as an input to assess motility of macro-parasites
(i.e. visible to the naked eye) in 12,24,48, and 96 well cell culture
plates for the purpose of high throughput screening of potential
anthelmintic drug compounds (Marcellino et al., 2012). The pro-
gram analyzes differences in worm position from successive video
frames to determine the rate of movement using the Lucas–Kanade
Optical ﬂow algorithm. The lower the movement, the lower the
motility number and more effective the compound is against the
parasite.
Our objective was to create a system functionally equivalent to
that described by Marcellino et al. (2012) that can be used with
microscopic stages of nematode parasites of human and veterinary
importance. The successful modiﬁcation and validation of this
image analysis system, which we call the ‘‘Worminator’’, provides
a new tool for quantifying the motility of microscopic nematode
stages. The Worminator provides a relatively low-cost, easy to
assemble platform for developing genera- and stage-speciﬁc assays
for measuring sensitivity to existing anthelmintics, as well as
screening new compounds for anthelmintic properties. The Wor-
minator assays developed to date have high efﬁciency and repro-
ducibility, low labor input, and yield objective data that is not
subject to scorer bias.2. Materials and methods
2.1. ‘‘Worminator’’ system
The open source ‘‘WormAssay’’ computer application described
by (Marcellino et al., 2012) is the core around which the ‘‘Wormi-
nator’’: system is built. The WormAssay application executes on an
Apple Mac desktop or laptop computer running Mac OS X.
Modiﬁcations to the WormAssay program were made to enable
the analysis of a single well (full video frame) containing multiple
organisms, while retaining the original multi-well (single organism
per well) full plate assay capability. Additionally, support was
added for HDMI input via Apple’s Thunderbolt I/O port using a
BlackMagic Design’s (Freemont, CA, USA) ‘‘Intensity Extreme’’
video capture unit to deliver the HDMI stream via Thunderbolt.
All of the aforementioned changes are contained in WormAssay
revision 1.4, whose source and executable code can be found at
https://code.google.com/p/wormassay. WormAssay version 1.4
requires Mac OS X 10.9 or later. A Canon Vixia HF M52 video
camera (Canon, Inc.) was used as the HD video capture input for
both micro and macroscopic assays. Macroscopic, full plate assays
were accomplished using a dark ﬁeld illuminator and plate holder
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Marcellino. Microscopic parasite stage assays utilized an Olympus
IX51 inverted microscope with the Canon Vixia HF M52 attached
via a Martin Microscope adapter, model MM99-58 (http://
www.martinmicroscope.com), and a Diagnostic Instruments DBX
1.0X C-mount adapter (http://www.spotimaging.com). An Olym-
pus PLAN-N 2x objective is used for L3 (700 microns) assays
and an Olympus PLANF-N 4x objective is used for mf (275
microns) assays. An Olympus Long Distance phase contrast con-
denser is used as a light source.
WormAssay’s ‘‘Assay Analyzer’’ option was set to ‘‘Consensus
Voting Luminance Difference (dArea)’’ and the ‘‘Plate Orientation’’
option was set to ‘‘No Plate Mode’’ for analyzing the motility of mf
and L3 stages. The ‘‘Assay Analyzer’’ option was set to ‘‘Lucas-
Kanade Optical Flow (Velocity, 1 organism per well)’’ with the
‘‘Plate Orientation’’ set to ‘‘Bottom-Read’’ for the Brugia malayi
adult parasites (Marcellino et al., 2012)
2.2. Parasites
B. malayi mf and adults, as well as the D. immitis mf were
sourced from the NIH/NIAID Filariasis Research Reagent Resource
Center (FR3; College of Veterinary Medicine, University of Georgia,
Athens, GA, USA). The D. immitis used in this study is a macrocyclic
lactone susceptible strain (2005 Missouri strain) maintained and
passaged in beagle dogs at the University of Georgia (Athens, GA).
A mixed population of L3 stage cattle GIN, was obtained from a
commercial beef operation in South Georgia. Coprocultures were
performed on pooled calf feces, and larvae were harvested after a
2 week incubation period using a Baermann apparatus (Dinaburg,
1942). These L3 were then used to infect a parasite free calf. Feces
from this calf were collected on days 14 through 18 post infection
and the resulting coproculture produced a mono-speciﬁc culture of
Cooperia punctata. These L3 were then used to infect another
parasite free calf to produce a mono-speciﬁc infection of Cooperia
punctata. Purity of the resulting infection was conﬁrmed by micro-
scopic examination of a random sample of several hundred L3
(Ministry of Agriculture, 1977).
2.3. Brugia malayi microﬁlariae assay (Nicotinic Agonists)
Peritoneally derived mf of B. malayi (124 mf/well) were
assayed in RPMI-1640 with L-Glutamine (RPMI) (BioWhittaker
#12-702F) containing 1% Penicillin/Streptomycin (P/S) (Sigma–
Aldrich #P4333) using 384-well, black with optically clear bottom,
tissue culture plates (Nunc, Inc., #142761).
10 mMstock solutions of pyrantel tartrate (PYR) (1-Methyl-2-(2-
[2-thienyl]ethenyl)-1,4,5,6 tetrahydropyrimidine, Sigma #P7674),
oxantel pamoate (OXA) (1-methyl-2-(3 hydroxyphenylethenyl)-
1,4,5,6-tetrahydropyrimidine, Sigma–Aldrich #O4755) and morantel
citrate salt (MOR) (1,4,5,6-tetrahydro-1-methyl-2-(2-[3-methyl-2-
thienyl]ethenyl)pyrimidine, Sigma–Aldrich #M5404) were pre-
pared using 100% dimethyl sulfoxide (DMSO) (Sigma–Aldrich
#D41639) and then serially diluted using RPMI + P/S to creatework-
ing solution concentrations of 300, 200, 140, 100, 60, 20, 6, and
2 lM,with a DMSO concentration of 2%. DMSOwas used as the neg-
ative control in concentration of 2% (v/v) in RPMI + P/S. A stock solu-
tion (10 mM) of Tribendimidine (TBDN) (Shandong Xinhua
Pharmaceutical CO, Ltd)was preparedwith absolute ethanol (ETOH)
(Sigma–Aldrich #E7023) and serially diluted with RPMI + P/S into
working concentrations of 300, 200, 140, 100, 60, 20, 6, and 2 lM
with an ETOH concentration of 2%. ETOH (2% (v/v)) in RPMI + P/S
was used as a negative control. All drug concentrations and controls
were run in triplicate. A volumeofworking solution equal to the vol-
umeof RPMI and P/S containing the B.malayimfwere added the cor-
responding plate wells to achieve ﬁnal drug concentrations of 150,100, 70, 50, 30, 10, 3, and 1 lM, with 1% (v/v) ETOH in RPMI + P/S
as a negative control. The plates were maintained at 37 C at 5%
CO2. Motility readings using the Worminator were taken 1 h, 2 h,
and24 h after addition of the drug solution to themf. Approximately
30 s of video was recorded and analyzed for each well at each
reading.
2.4. Brugia malayi microﬁlariae assay (macrocyclic lactones)
10 mM stock solutions of ivermectin (IVM) (22,23-dihydroaver-
mectin B1, Sigma–Aldrich # I8898), eprinomectin (EPR) ((400R)-400-
(Acetylamino)-400-deoxy-avermectin B1, Sigma–Aldrich #32526),
doramectin (DOR) (25-Cyclohexyl-5-O-demethyl-25-de(1-methyl-
propyl)avermectin, Sigma–Aldrich #33993), and moxidectin
(MOX) (VETRANAL™ analytical standard Sigma–Aldrich #33746)
were prepared in both DMSO and in propylene glycol (PG)
(Sigma–Aldrich #PHR1051) and diluted in RPMI + 1% P/S to create
working solutions of 0.002, 0.02, 0.2, 2, 4, 12, 20, 40 and 100 lM.
Negative controls with 2% (v/v) DMSO in RPMI + P/S, and 2%
PG(v/v) in RPMI + P/S were also prepared. Working solutions were
dispensed into 0.5 ml micro-centrifuge tubes, with B. malayi mf
added in equal volumes for ﬁnal concentrations of 0.001, 0.01,
0.1, 1, 2, 6, 10, 20 and 50 lM with 1% (v/v) DMSO and PG controls.
Tubes were mixed using a vortex mixer (Fisher Scientiﬁc
#02215365) for 5–7 s at medium speed setting (5.5) (for each well)
and then pipetted immediately into the 384 well plate (NUNC
black with optically clear bottom #142761) for a total of 50 ll
per well containing approximately 100 mf each. Wells surrounding
those containing parasites and drug were ﬁlled with 50 ll RPMI
1640 containing 1% Pen/Strep to reduce evaporation during incu-
bation. Plates were kept in a 37 C incubator with 5% CO2 for
24 h and then read using the Worminator system scanning each
well for approximately 30 s.
2.5. Brugia malayi adult assay
Stock solutions of 10 mM ivermectin and 10 mM moxidectin
serially diluted using 100% DMSO to yield stock working solution
concentrations of 10.0, 5.00, 2.50, 1.25, 0.625, 0.313, 0.156, 0.078,
0.039, 0.0195, and 0.0097 mM in 100% DMSO. These working stock
solutions were each further diluted 50 fold using incubation med-
ium (described below) in order to create a ﬁnal set of working solu-
tion with 2% DMSO and drug concentrations of 200, 100, 50, 25,
12.5, 6.25, 3.13, 1.56, 0.781, 0.391, and 0.195 lM of each drug.
One adult female B. malayi was added to an individual well of a
24 well cell culture plate (Corning Costar #3524) in 1 mL of med-
ium comprised of 83% RPMI-1640, 10% heat inactivated Fetal
Bovine Serum (Sigma–Aldrich #F4135), 5% Penicillin/Streptomycin
(Sigma–Aldrich #P4333), and 2% Gentamicin Sulfate Salt (Sigma–
Aldrich #G12).
One mL of each ﬁnal working solution was added to a pair of
wells in order to further achieve a ﬁnal DMSO concentration of
1% and ﬁnal anthelmintic concentrations of 100, 50, 25, 12.5,
6.25, 3.13, 1.56, 0.781, 0.391, 0.195, and 0.097 lM. Negative con-
trol wells contained 1% DMSO. The prepared plate was then incu-
bated at 37 C and 5% CO2 for 48 h. Worminator readings were
taken prior to addition of the drug, immediately following addition
of the drug, and at 1, 12, 18, 24, 36, and 48 h post addition of the
drug.
2.6. Diroﬁlaria immitis assays
Stock solutions of ivermectin, doramectin, and moxidectin were
prepared in DMSO and PG and diluted in RPMI with 1% P/S to cre-
ate working solutions of 0.002, 0.02, 0.2, 2, 4, 8, 12, 16, 20, 40,
100 lM and controls of 2% (v/v) DMSO and PG. D. immitis mf were
Fig. 1. Worminator system (left to right) Dark ﬁeld illuminator/plate holder,
inverted microscope with camera attached, microscope light controller with
BlackMagic ‘‘Intensity Extreme’’ video converter positioned on top, and 27’’ iMac
with WormAssay user interface window.
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lariae were added to wells along with drug yielding ﬁnal drug con-
centrations of 0.001, 0.01, 0.1, 1, 2, 4, 6, 8, 10, 20, and 50 lM with
1% (v/v) DMSO and PG controls. Plates were then incubated at
37 C with 5% CO2 for 24 h. Worminator readings were taken once
24 h after addition of the drug.
2.7. Cooperia spp. L3 assays
Initial stock solutions of 10 mM ivermectin and 10 mM moxi-
dectin were prepared using 100% DMSO as a solvent. Initial stock
solutions were then diluted in 100% DMSO to yield 1.0, 0.50,
0.25, 0.125, 0.0625, 0.0313, 0.0156, and 0.0078 mM working stock
solutions for each drug. These stock solutions were each diluted 50
fold in deionized water yielding working concentrations of 20, 10,
5, 2.5, 1.25, 0.625, 0.313, and 0.156 lM.
Approximately 50 L3 were added to each well of a 96-well, ﬂat
bottom, non-treated, black with clear bottom, non-sterile plate
(Corning Costar #3631) in 150 lL of deionized water. 150 lL of
each drug solution was then added to respective wells to arrive
at a ﬁnal DMSO concentration of1% and ﬁnal anthelmintic concen-
trations of 10, 5, 2.5, 1.25, 0.625, 0.313, 0.156, and 0.78 lM. Nega-
tive control wells containing 1% DMSO in deionized water were
also formulated. Assay plates were placed in an incubator at
25 C for 48 h and Worminator readings were taken immediately
prior to adding drug, immediately after adding drug, and at 1, 12,
18, 24, 36, and 48 h post addition of drugs.
2.8. Data and analysis
The Worminator output is written to two comma separated
value (CSV) ﬁles; one contains the average of the motion detected
in the individual well for the analyzed period for each well or plate
tested, and a second ﬁle contains the underlying raw values used in
determining the aforementioned averages. The average motility
scores for the three technical replicates of each drug concentration
were used in the analysis. The average motility for the control
wells was calculated by averaging the average motility results of
the three negative control wells on each plate. The results for the
drug containing wells were analyzed in terms of percent inhibition
of motility at each concentration as compared to the control wells,
with a higher percentage motility unit inhibition interpreted as a
higher level of drug activity (effectiveness).
%Motility inhibition
¼ ðAverage control motility unitsAverage treated motility unitsÞ
Average control motility units
 
 100
These values were calculated across drug concentrations and
time periods using Microsoft Excel (Microsoft, 2013).
Dose response analysiswas performedwithGraphPadPrismver-
sion 6.00 using a variable slope nonlinear regressionmodel (Graph-
Pad Software, La Jolla, California, USA, http://www.graphpad.com).
Drug concentrations were log10 transformed prior to analysis. The
‘‘log (inhibitor) vs response (fourparameters) logistic equation’’ out-
put provided IC50 values, as well as dose response curves for each
drug and time point tested.
3. Results
3.1. Worminator
Worm assay version 1.01 was modiﬁed to support motility
analysis of microscopic parasites, as well as support for current
production computer and video equipment (see Section 2.1). Theresulting WormAssay version 1.4 was used in the Worminator sys-
tem for the data presented in this paper (Fig. 1). Version 1.4 and
the listed equipment are capable of processing 5–12 video frames
per second, which provides more than adequate sensitivity for
accurate motility analysis of adult, larval, and mf stages of nema-
tode parasites.
Several types of microscopes were tested for use in the
Worminator system, but we found that an inverted microscope
(Olympus IX51) provided the best depth of ﬁeld and eliminated
the meniscus-induced optical distortion encountered with com-
pound or dissection microscopes. An additional beneﬁt of the
inverted microscope is the X–Y positioning stage, which facilitates
easy and smooth movement from plate well to plate well. Tissue
culture plates having optically clear and ﬂat bottoms must be used.
Additionally, nematodes tend to sink to the bottom of the well,
thereby placing more of them in the same plane of focus near
the bottom of the well. Objective lenses were selected such that
a full well ﬁeld of view was delivered to the video camera (2
objective for 96 well plates and 4 objective for 384 well plates).
Video camera zoom was then adjusted such that the well occupied
90% of the camera’s LCD view screen (Fig. 2). WormAssay shows
in real time the recorded mean movement unit (mmu) and stan-
dard deviation for the well currently being scanned and analyzed.
Numerous experiments were carried out to determine an optimal
scanning time period that would provide an accurate motility mea-
surement, while minimizing excessive scanning time. Readings
were determined to have stabilized when standard deviation of
mmu decreased to less than 2 mmu. In most cases, this occurred
after 15–20 s of scanning, depending on the species and size plate
being used. Based on these observations and the inclusion of a
‘‘safety margin’’, a standard scan time of 30 seconds was estab-
lished for all assays.
Assays performed on macroscopic parasites (e.g. B. malayi
adults) can be performed in 6, 12, 24, or 48 well plates (supported
by WormAssay’s automatic plate detection feature), depending on
the physical size of the parasite species. Clear, ﬂat bottom, non-
treated, polystyrene plates provided very good results. Assays on
B. malayi adults (50 mm  150 lm) worked best in 24 well plates
(Corning, Costar #3738).
Assays performed on microscopic parasites require 96 or 384
well plates, depending on the size/life stage of the parasite. The
physical size of B. malayi and Cooperia spp. L3 permitted Wormina-
tor assays to be performed using 96 well plates. However, 96 well
plates were unsuccessful with B. malayi and D. immitis mf due to
this life stage being very small in size; the higher magniﬁcation
Fig. 2. Worminator system video input for 96 well and 384 well plates. (A) is the raw video input to WormAssay of Brugia malayi L3 in a 96 well plate. (B) is the real time
display from WormAssay of Brugia malayi L3 in 2A (red shading indicates movement, blue shading indicates lack of movement). (C) is the raw video input for Brugia malayi
microﬁlariae in a 384 well plate. (D) is the real time display from WormAssay. (Image obtained from 2700 iMac display screen capture using Apple OS X 10 native screen
capture function. Image collage created in Adobe Photoshop CS6, version 13.0.1  64 (Adobe Systems, Inc. San Jose, CA). Post processing limited to Photoshop auto white
balance correction).
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overcome by using 384 well plates, which corralled the mf in an
area that permitted adequate magniﬁcation as well as a full well
view to be analyzed by WormAssay. Additionally, black with opti-
cally clear bottom 96 well and 384 well plates eliminated errant
readings resulting from stray reﬂections and/or shadows.
3.2. Brugia malayi adult assay
B malayi female adult worms were assayed using the Wormina-
tor system and the macrocyclic lactone anthelmintics ivermectin
and moxidectin. Dose responses were calculated using both
parasite mean motility units (mmu) and percent change (%D) in
parasite motility relative to negative controls vs log drug concen-
tration (Table 1, Fig. 3). Hyper-motility, where the motility of the
treated parasites increased relative to the controls was evident at
the lower ivermectin concentrations. This produced a negative
inhibition, which is seen in the % inhibition vs log concentration
of ivermectin dose response curve (Fig. 3).
3.3. Brugia malayi microﬁlariae assay
B. malayi mf were assayed with the Worminator system using
two different classes of anthelmintics: macrocyclic lactones and
nicotinic agonists. The nicotinic agonist drugs utilized werelevamisole, pyrantel, morantel, oxantel, and tribendimidine.
Results from the 24 h Worminator readings are summarized in
Table 1 and Fig. 4, with the exception of levamisole. We found that
the paralytic effect of levamisole was very short-lived (<60 min);
this prevented the gathering of consistent well-to-well dose
response data.
Three macrocyclic lactone anthelmintics were tested against B.
malayimf; ivermectin, moxidectin, and doramectin. We found that
moxidectin dissolved using PG was more effective at inhibiting
motility than moxidectin dissolved DMSO. Data are presented in
Table 1 and Fig. 5.
3.4. Cooperia spp. L3 assays
Cooperia spp. L3 were tested using the macrocyclic lactone
anthelmintics ivermectin and moxidectin. Dose responses were
calculated using both parasite mean motility units (mmu) and per-
cent change (%D) in parasite motility relative to negative controls
vs log drug concentration (Fig. 6). Dose response curves and IC50
data are presented in Fig. 6 and Table 1.
3.5. Diroﬁlaria immitis microﬁlariae assays
D immitis mf were assayed using the macrocyclic lactone drugs
ivermectin, moxidectin, and doramectin. Results from ivermectin
Table 1
Dose response analysis of Worminator output for all parasite species and drug combinations tested. A Variable slope nonlinear regression model analysis using GraphPad Prism 6
was performed using mean motility units (mmu) vs log concentration (column heading IC50 mmu) and per cent change mmu vs control mmu vs log concentration (column
heading IC50 %D).
Parasite species Stage Drug Time (h) IC50 mmu (lM) SEM R2 IC50 %D (lM) SEM R2
B. malayi Adult IVM 24/48 2.22/1.37 1.11/1.12 0.92/0.89 2.24/1.28 1.21/1.10 0.79/0.93
B. malayi Adult MOX 24/48 2.85/1.26 NA/1.23 0.75/0.79 3.01/1.19 NA /1.20 0.61/0.83
B. malayi mf OXA 24 47.63 1.09 0.92 50.49 1.15 0.82
B. malayi mf MOR 24 30.85 1.09 0.96 42.38 1.15 0.92
B. malayi mf PYR 24 40.50 1.11 0.89 41.44 1.05 0.97
B. malayi mf TBDN 24 48.76 1.18 0.70 46.13 1.05 0.87
B. malayi mf IVM 24 6.136 1.11 0.92 5.884 1.16 0.89
B. malayi mf MOX-DMSO 24 5.759 NA 0.1 1.453 2.11 0.19
B. malayi mf MOX-PG 24 12.02 9.74 0.67 11.75 3.61 0.65
B. malayi mf DOR 24 8.095 5.15 0.92 7.162 1.91 0.96
D. immitis mf IVM 24 43.03 NA 0.27 28.2 2.94 0.59
D. immitis mf MOX 24 9.288 2.64 0.16 9.008 1.79 0.26
D. immitis mf DOR 24 2.778 1.62 0.81 2.765 1.52 0.82
Cooperia spp. L3 IVM 48 1.69 1.29 0.81 1.75 1.31 0.82
Cooperia spp. L3 MOX 48 1.52 1.34 0.68 1.45 1.34 0.66
Key to abbreviations: Standard error of mean (SEM), microﬁlariae (mf), ivermectin (IVM), moxidectin (MOX), oxantel pamoate (OXA), doramectin (DOR), tribendimidine
(TBDN), pyrantel pamoate (PYR), morantel tartrate (MOR), propylene glycol (PG), Not applicable (NA) e.g. model did not converge.
Fig. 3. Brugia malayi adult female worm mean motility unit (mmu) and dose response curves for ivermectin and moxidectin. Curves were generated applying the variable
slope nonlinear regression model analysis contained in GraphPad Prism 6. Broken vertical lines indicate IC50 values.
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obtained using B. malayi mf, and we were unable to generate good
ﬁts for the dose–response data generated using these drugs (Fig. 7).
In contrast, we were able to obtain reliable ﬁts to the data using
doramectin; the R2 values for these two curves for doramectin
were 0.818 and 0.8112, whereas the R2 values for ivermectin and
moxidectin ranged from 0.16 to 0.59.4. Discussion
The ‘‘Worminator’’ system is a novel application of real time,
computer analyzed, HD video that permits the detection, measure-
ment and characterization of anthelmintic effects on motility of
microscopic life stages of parasitic nematodes. This system usesopen source software and reasonably priced off the shelf computer
and video imaging equipment, making it practical for almost any
laboratory. The Worminator addresses the important need for
practical, cost-efﬁcient, and robust in vitro assays to screen com-
pounds for anthelmintic activity, as well as for characterization
of anthelmintic sensitivity in nematode populations. (Boatin
et al., 2012; Vercruysse et al., 2012).
To create the Worminator System we adapted and integrated
current technology to function in concert with the WormAssay
computer application. Our goal was for a simple and relatively
inexpensive general purpose assay that is accurate and repeatable
while also able to support analysis of most species of parasitic
nematodes in their various life stages. The ability of the Wormina-
tor system to assess in vitro anthelmintic sensitivity in a variety of
parasite species and life stages ranging from mf (200 um) to L3
Fig. 4. Brugia malayi microﬁlaria mean motility unit (mmu) and dose response curves for nicotinic class anthelmintics. Curves were generated applying a variable slope
nonlinear regression model analysis contained in GraphPad Prism 6. Broken vertical lines indicate IC50 values.
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data presented here. Additionally, the real-time quantitative data
capture of the Worminator system enables new observations that
would be extremely difﬁcult to make with other available in vitro
assays. One such observation is that all species and stages ofparasites tested with macrocyclic lactone anthelmintics demon-
strated an increase in motility at low concentrations as compared
to the no-drug control. Though our laboratory has a great deal of
experience using the larval migration inhibition assay with macro-
cyclic lactone drugs in multiple parasite species (Evans et al.,
Fig. 5. Brugia malayimicroﬁlaria mean motility unit (mmu) and dose response curves for macrocyclic lactone class anthelmintics. Curves were generated applying a Variable
slope nonlinear regression model analysis contained in GraphPad Prism 6. Note differences in the moxidectin dissolved using DMSO as compared to moxidectin dissolved in
PG. Broken vertical lines indicate IC50 values.
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this ‘‘hyper-motility’’ can be seen in the dose response curves con-
tained in Figs. 4–6.
The Worminator System provided informative dose response
data with both B. malayi mf and adults. The greatest sensitivityfor B. malayi adults when tested against ivermectin and moxidectin
was seen at the 48 h time point (Fig. 3). The IC50 results obtained
are similar to those reported by Marcellino et al. (2012) for B.
malayi adults with ivermectin. In contrast to the adult B. malayi
worms, the mf stage demonstrated a different dose–response
Fig. 6. Cooperia spp. L3 larvae mean motility unit (mmu) and dose response curves for ivermectin and moxidectin. Curves were generated applying the variable slope
nonlinear regression model analysis contained in GraphPad Prism 6. Broken vertical lines indicate IC50 values.
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lactone drugs demonstrated a threshold effect where there was lit-
tle decrease in motility over a wide range of concentrations, and
then a rapid decrease in motility over a narrow range of relatively
high concentrations (Fig. 5). A similar in vitro dose–response phe-
notype was also observed in a previous study, which used visual
scoring of B. malayi mf exposed to ivermectin and moxidectin
(Tompkins et al., 2010). The nature of this dose response pheno-
type yielded a high level of variability between assays, resulting
in high S.E.M. values for the IC50. We also noted a very poor dose
response of B. malayi mf to moxidectin when dissolved in DMSO;
however, when the moxidectin was dissolved in PG, the response
was similar to the other macrocyclic lactone drugs tested (Fig. 5).
We speculate that this is attributable to the poor aqueous solubil-
ity of moxidectin, and that the PG increased the solubility of moxi-
dectin. Future experiments will investigate further the differences
in dose–response for macrocyclic lactone drugs dissolved in DMSO
vs PG using a variety of different parasite species and stages.
In contrast to the macrocyclic lactone drugs, dose–response
data for B. malayi mf with nicotinic agonists were very consistent
across all four drugs tested (OXA, PYR, MOR, and TBDN), as indi-
cated by similar IC50 values, small IC50 S.E.M. values and high R2
values for the nonlinear curve ﬁt. To our knowledge there are no
similar published data to compare these results to, however, these
data are consistent with electrophysiological responses of muscle
from B. malayi adults, which shows that paralysis is the primary
mode of action of nicotinic agonist anthelmintics (Robertson
et al., 2013). It is also widely accepted that a primary mechanism
of action for the macrocyclic lactone anthelmintics is paralysis of
somatic musculature, due to irreversible binding at glutamate
gated chloride channels that produces a long-lasting hyperpolar-
ization of the neuron or muscle cell, therefore blocking furtherfunction (Wolstenholme and Rogers, 2005; Kotze et al., 2012). Con-
sistent with this belief, in vitro measurements of muscle contrac-
tion and motility-based assays such as the LMIA can be used to
detect resistance to the macrocyclic lactones in strongylid species
(Demeler et al., 2010a,b, 2014). However, when results of the B.
malayi mf nicotinic agonist assays are compared with results of
the macrocyclic lactone assays, a distinct contrast is apparent.
The IC50 S.E.M values for the macrocyclic lactones are much
greater, and the slopes of the dose–response curves for the macro-
cyclic lactone drugs are much steeper. Additionally, the macrocy-
clic lactone concentrations required to induce paralysis are
thousands of times higher than tissue levels achieved following a
therapeutic dose (Evans et al., 2013). Taken together, these data
support suggestions that inhibition of motility may not be a pri-
mary mechanism of action for the macrocyclic lactone drugs in
ﬁlarioid nematodes (Geary et al., 1993; Moreno et al., 2010;
Vatta et al., in press), and thus would not be a good phenotypic
measure for diagnosing resistance to these drugs.
The dose–response data obtained for D. immitis mf using the
Worminator system were the least intuitive of any of the parasite
species/life stage tested. Only doramectin produced a sigmoidal
dose response, though the slope was very steep. With ivermectin
and moxidectin there was only a minimal decline in motility over
a wide range of concentrations, with only a modest decline even at
the highest concentrations tested. With both of these drugs, inhibi-
tion of motility never exceeded 75%, even at maximal achievable
in vitro concentrations (using DMSO as a solvent) (Fig. 7). Given
this dose–response phenotype to ivermectin and moxidectin in a
drug-susceptible isolate (Missouri 2005), it seems highly unlikely
that motility of mf could ever be a useful in vitro assay for detecting
resistance to macrocyclic lactone drugs in D. immitis, when using
these drugs. However, using other macrocyclic lactone drugs, such
Fig. 7. Diroﬁlaria immitis microﬁlaria mean motility unit (mmu) and dose response curves for macrocyclic lactone class anthelmintics. Curves were generated applying a
Variable slope nonlinear regression model analysis contained in GraphPad Prism 6. Broken vertical lines indicate IC50 values.
242 B. Storey et al. / International Journal for Parasitology: Drugs and Drug Resistance 4 (2014) 233–243as doramectin, further assay optimization might overcome this
obstacle.
We have presented data demonstrating the ability of the
Worminator System to quantify parasite motility for three differ-
ent nematode parasites from two different phylogenetic clades,
using three different life stages and seven different anthelmintics.
These data demonstrate the utility of the Worminator System as a
practical, efﬁcient and robust tool for measuring the in vitro
sensitivity of various nematode parasite species and stages to
anthelmintics. Though only drug-susceptible parasite isolates were
used in these initial studies, future work will compare these with
drug-resistant isolates, with the goal of optimizing diagnostic
assays for detecting drug resistance in nematode populations. In
conclusion, the Worminator system provides a computer based
quantitative platform that is simple and efﬁcient to use, provides
improved sensitivity and objectivity over previously used motility
assays, is agnostic to parasite life stage, and can be setup in anylaboratory at a reasonable cost. Given these advantages compared
to other available in vitro diagnostic systems for measuring
susceptibility of nematodes to anthelmintic compounds, the Wor-
minator should permit the development of multiple species- and
drug-speciﬁc assays that will advance discovery of new anthelmin-
tic compounds, as well as improve the monitoring of nematode
populations for changes in their sensitivity to existing anthelmintic
compounds.
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